权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Epigenetic Control of Kidney Fibrosis

肾脏纤维化的表观遗传控制

基本信息

批准号：
9067142
负责人：
WENZHENG ZHANG
金额：
$ 23.7万
依托单位：
ALBANY MEDICAL COLLEGE
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
起止时间：
2009-03-01 至 2020-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9067142
关键词：
Ablation Adverse effects Age Albuminuria Aldosterone Atrasentan Biological Models Biopsy Blood Cardiac Cells Cessation of life Chronic Kidney Failure Cicatrix Clinical Research DNA Data Development Diabetes Mellitus Diabetic Nephropathy Disease Disease Progression Duct (organ) structure Edema End stage renal failure Endothelin-1 Epigenetic Process Fibrosis Foundations Gene Targeting Genes Genetic Genetic Markers Genetic Screening Genetic screening method Glomerular Filtration Rate Goals HK2 gene Health Histone H3 Human Hypertension Hypotension Infusion procedures Injury Kidney Kidney Failure Knock-out Knockout Mice Link Malignant Neoplasms Mediating Methyltransferase Modeling Molecular Mus Mutation Patients Pharmaceutical Preparations Physiological Play Polycystic Kidney Diseases Pre-Clinical Model Public Health Publishing Renal function Renin-Angiotensin-Aldosterone System Repression Role Site Somatic Mutation Spironolactone Streptozocin Susceptibility Gene Technology Testing Tubular formation Up-Regulation Vasoconstrictor Agents Work autocrine cost diagnostic biomarker effective therapy functional loss genetic manipulation high risk hyperkalemia improved in vivo inhibitor/antagonist laser capture microdissection mouse model new therapeutic target next generation sequencing novel novel therapeutics paracrine preconditioning targeted treatment

项目摘要

DESCRIPTION (provided by applicant): Kidney fibrosis is the hallmark of chronic kidney disease (CKD). Despite aggressive management, CKD often progresses to end-stage renal disease, which costs the US >$40 billion dollars and >90,000 deaths annually. The current main therapy targeting the renin-angiotensin-aldosterone (aldo) system with drugs including Spironolactone often delays, but does not stop the progression. This is also true for all other drugs such as endothelin 1 (ET1) blocker Atrasentan. The ineffectiveness and side effects including hyperkalemia and edema necessitate identification of novel therapeutic targets for the development of more effective treatments. Factors modulating the aldo global effect from its primary action site connecting tubule/collecting duct (CNT/CD) may prove better targets. However, such genetic and epigenetic factors remain virtually unknown, partially because of the intrinsic limitations of the clinical studies. These limitations include lack of kidney biopsies to verify the status of the disease, impossibility of genetic manipulation in patients to establish th causative relationship, and impracticability through mutational analyses with blood DNA to identify somatic mutations, which occur at atypical high rate in human kidney. Our published and preliminary data suggest that 1) Patients with diabetic nephropathy (DN) and CKD may have mutations in histone H3 K79 methyltransferase hDOT1L and abolished H3 dimethylation (H3m2K79) in their kidney biopsies; 2) Dot1a (encoded by Dot1l) represses ET1 and other aldo target genes. Aldo relieves Dot1a-mediated repression by multiple mechanisms; 3) CNT/CD-specific ablation of Dot1l in Dot1lAC mice causes abolition of H3m2K79, upregulation of ET1, and development of severe kidney fibrosis throughout the whole kidney. Accordingly, in this proposal, we will develop genetic markers to overcome the above limitations. To this end, we will use kidney biopsies from patients with DN and CKD, our mouse models bearing intact or disrupted Dot1l and ET1 in the CNT/CD, and their CNT/CD primary cells in combination of cutting-edge technologies including laser capture microdissection, next generation sequencing, and in vivo lineage tracing. Our specific aims are to study if DN and CKD patients have genetic defects in hDOT1L (Aim 1), study if Dot1l deletion accelerates kidney fibrosis in part by upregulating ET1 in mice (Aim 2), and study if Dot1a and ET1 modulate the global effect of aldo profibrotic action (Aim 3). Our studies may identify DOT1L as a novel repressor of ET1 and thus a new renoprotective factor, confirm loss of DOT1L function and thus H3m2K79 as an epigenetic driver of CKD, define Spironolactone + Atrasentan as a new effective combinational therapy of CKD, and lay the foundation of new genetic tests. If Dot1l and ET1 are genetically linked to CKD in humans, they may be exploited to develop genetic screening tests to identify patients at high risk of CKD and to determine their responsiveness to various aldo and ET1 inhibitors. Like ET1, DOT1L can also be considered as a potential new therapeutic target of CKD.

描述（由申请人提供）：肾纤维化是慢性肾脏疾病（CKD）的标志。尽管进行了积极的治疗，CKD经常发展为终末期肾脏疾病，每年造成美国400亿美元的损失和9万美元的死亡。目前针对肾素-血管紧张素-醛固酮（aldo）系统的主要治疗方法是使用包括螺内酯在内的药物，通常会延迟，但不能阻止其进展。这也适用于所有其他药物，如内皮素1 （ET1）阻滞剂阿特拉森。无效和副作用，包括高钾血症和水肿，需要确定新的治疗靶点，以开发更有效的治疗方法。从连接小管/集束管（CNT/CD）的主要作用部位调节aldo全局效应的因子可能是更好的靶点。然而，这些遗传和表观遗传因素实际上仍然未知，部分原因是临床研究的内在局限性。这些限制包括缺乏肾活检

项目成果

期刊论文数量（23）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Dot1l deficiency leads to increased intercalated cells and upregulation of V-ATPase B1 in mice.

DOI：
10.1016/j.yexcr.2015.09.014
发表时间：
2016-06-10
期刊：
Experimental cell research
影响因子：
3.7
作者：
Xiao Z;Chen L;Zhou Q;Zhang W
通讯作者：
Zhang W

AF17 facilitates Dot1a nuclear export and upregulates ENaC-mediated Na+ transport in renal collecting duct cells.

DOI：
10.1371/journal.pone.0027429
发表时间：
2011
期刊：
PloS one
影响因子：
3.7
作者：
Wu H;Chen L;Zhou Q;Zhang W
通讯作者：
Zhang W

Widely expressed Af17 is likely not required for embryogenesis, hematopoiesis, and animal survival.

DOI：
10.1002/dvg.20679
发表时间：
2010-12
期刊：
GENESIS
影响因子：
1.5
作者：
Zhang, Zhijing;Huang, Le;Reisenauer, Mary Rose;Wu, Hongyu;Chen, Lihe;Zhang, Yujin;Xia, Yang;Zhang, Wenzheng
通讯作者：
Zhang, Wenzheng

Epigenetics of epithelial Na(+) channel-dependent sodium uptake and blood pressure regulation.

上皮Na(+)通道依赖性钠摄取和血压调节的表观遗传学。